Filgotinib induced and maintained clinical remission among patients with moderate to severe ulcerative colitis who had not responded to other therapies in a phase 2b and 3 trial published in The Lancet. The oral Janus kinase 1 preferential inhibitor has been previously evaluated in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
The trial included 1348 patients who were randomly assigned to receive 200 mg or 100 mg of filgotinib or placebo once a day for 11 weeks. The 664 patients who had clinical remission or a response at week 10 entered the maintenance study, in which they were randomized to continue filgotinib or switch to placebo.
Slomski A. Filgotinib Induces and Maintains Ulcerative Colitis Remission. JAMA. 2021;326(4):299. doi:10.1001/jama.2021.11750
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: